Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $1,194,633.36 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 47,709 shares of the business’s stock in a transaction on Thursday, April 11th. The shares were sold at an average price of $25.04, for a total transaction of $1,194,633.36. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Samuel Kintz also recently made the following trade(s):

• On Monday, March 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $17.56, for a total transaction of $210,720.00.
• On Thursday, January 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $15.69, for a total transaction of $188,280.00.

Enliven Therapeutics Price Performance

Shares of NASDAQ:ELVN opened at $17.30 on Thursday. The business has a fifty day moving average price of $16.98 and a 200-day moving average price of $14.31. The company has a market capitalization of $712.76 million, a PE ratio of -7.90 and a beta of 1.06. Enliven Therapeutics, Inc. has a 1-year low of $9.80 and a 1-year high of $26.00.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.09. On average, sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -2.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Mizuho started coverage on Enliven Therapeutics in a research note on Tuesday, April 9th. They issued a “buy” rating and a $34.00 price target on the stock.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Barclays PLC bought a new stake in shares of Enliven Therapeutics in the 1st quarter worth $158,000. Bank of New York Mellon Corp purchased a new stake in shares of Enliven Therapeutics during the first quarter valued at $335,000. Tower Research Capital LLC TRC bought a new stake in Enliven Therapeutics in the 1st quarter worth about $36,000. Citigroup Inc. purchased a new position in Enliven Therapeutics in the 1st quarter worth about $247,000. Finally, Dimensional Fund Advisors LP bought a new position in Enliven Therapeutics during the 1st quarter valued at about $217,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.